Three thoracic medical oncologists examine the limited next-line options for advanced squamous non-small cell lung cancer after immunotherapy and platinum-based chemotherapy, and discuss emerging antibody-drug conjugates, bispecific antibodies, and tumor-selective CTLA-4 targeting, including early PRESERVE-003 data with gotistobart, alongside immune-related adverse event management, patient selection, and clinical trial access in practice.
Balazs Halmos, MD, frames the program around advanced squamous non-small cell lung cancer (NSCLC) that progresses after immunotherapy and platinum-based chemotherapy, a setting in which docetaxel remains a standard next-line option and progress has been slow.
Balazs Halmos, MD, raises the French PERSEE trial, in which chemoimmunotherapy outperformed immunotherapy alone in non-small cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression.
